Business Context and Reporting Period
This Form 8-K is filed by Vital Therapies, Inc. (noted as IMMUNIC, INC. in request metadata) for the reporting date of March 29, 2017. The filing addresses a specific corporate event related to a previously disclosed underwritten public offering.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the capital raise event:
- Shares Purchased: 1,312,500 shares of common stock.
- Offering Price: $4.00 per share.
- Transaction Type: Full exercise of the underwriters' option to purchase additional shares.
Material Changes
The material change reported is the full exercise of the underwriters' option to purchase an additional 1,312,500 shares. This action increases the total capital raised from the public offering. The filing text does not provide a clear value for the total gross proceeds or the net proceeds after underwriting discounts.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the capital raise. The event is presented as a completion of a previously announced transaction.
Investor Verification Checklist
- Verify the total gross proceeds generated by the full exercise of the option (1,312,500 shares x $4.00).
- Confirm the specific underwriting discount percentage to calculate net proceeds.
- Review the attached Exhibit 99.1 (Press Release) for details on the use of proceeds.
- Check subsequent filings for the updated share count and dilution impact.